CAMP4 Therapeutics Corporation Logo

CAMP4 Therapeutics Corporation

CAMP

(0.5)
Stock Price

5,20 USD

-42.76% ROA

280.7% ROE

-0.15x PER

Market Cap.

660.336,00 USD

-326.3% DER

0% Yield

-77.36% NPM

CAMP4 Therapeutics Corporation Stock Analysis

CAMP4 Therapeutics Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CAMP4 Therapeutics Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.4x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-150.55%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-8.65%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The stock is burdened with a heavy load of debt (2338%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-4), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

CAMP4 Therapeutics Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CAMP4 Therapeutics Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

CAMP4 Therapeutics Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CAMP4 Therapeutics Corporation Revenue
Year Revenue Growth
1986 14.600.000
1987 7.700.000 -89.61%
1988 7.500.000 -2.67%
1989 9.100.000 17.58%
1990 10.900.000 16.51%
1991 14.300.000 23.78%
1992 20.600.000 30.58%
1993 35.800.000 42.46%
1994 40.700.000 12.04%
1995 45.700.000 10.94%
1996 61.600.000 25.81%
1997 49.300.000 -24.95%
1998 46.900.000 -5.12%
1999 37.100.000 -26.42%
2000 85.628.000 56.67%
2001 124.979.000 31.49%
2002 100.715.000 -24.09%
2003 100.044.000 -0.67%
2004 128.616.000 22.21%
2005 220.027.000 41.55%
2006 217.493.000 -1.17%
2007 222.339.000 2.18%
2008 140.907.000 -57.79%
2009 98.370.000 -43.24%
2010 112.113.000 12.26%
2011 114.333.000 1.94%
2012 138.728.000 17.58%
2013 180.579.000 23.18%
2014 235.903.000 23.45%
2015 250.606.000 5.87%
2016 280.719.000 10.73%
2017 351.102.000 20.05%
2018 365.912.000 4.05%
2019 363.800.000 -0.58%
2020 366.107.000 0.63%
2021 308.587.000 -18.64%
2022 295.839.000 -4.31%
2023 294.949.000 -0.3%
2024 214.500.000 -37.51%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CAMP4 Therapeutics Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 3.200.000 100%
1996 4.400.000 27.27%
1997 5.800.000 24.14%
1998 4.500.000 -28.89%
1999 4.800.000 6.25%
2000 5.215.000 7.96%
2001 6.979.000 25.28%
2002 7.583.000 7.97%
2003 5.982.000 -26.76%
2004 5.363.000 -11.54%
2005 8.320.000 35.54%
2006 9.109.000 8.66%
2007 15.015.000 39.33%
2008 15.710.000 4.42%
2009 12.899.000 -21.79%
2010 10.943.000 -17.87%
2011 11.125.000 1.64%
2012 11.328.000 1.79%
2013 14.291.000 20.73%
2014 21.052.000 32.12%
2015 19.854.000 -6.03%
2016 19.803.000 -0.26%
2017 22.005.000 10.01%
2018 25.761.000 14.58%
2019 27.656.000 6.85%
2020 29.436.000 6.05%
2021 25.811.000 -14.04%
2022 28.444.000 9.26%
2023 24.570.000 -15.77%
2024 16.204.000 -51.63%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CAMP4 Therapeutics Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 12.087.000 100%
2010 10.523.000 -14.86%
2011 8.858.000 -18.8%
2012 10.984.000 19.36%
2013 12.154.000 9.63%
2014 14.416.000 15.69%
2015 15.578.000 7.46%
2016 25.065.000 37.85%
2017 55.901.000 55.16%
2018 52.089.000 -7.32%
2019 31.070.000 -67.65%
2020 57.669.000 46.12%
2021 49.077.000 -17.51%
2022 52.333.000 6.22%
2023 51.819.000 -0.99%
2024 40.456.000 -28.09%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CAMP4 Therapeutics Corporation EBITDA
Year EBITDA Growth
1986 -4.700.000
1987 1.200.000 491.67%
1988 1.000.000 -20%
1989 200.000 -400%
1990 600.000 66.67%
1991 -100.000 700%
1992 2.600.000 103.85%
1993 5.200.000 50%
1994 4.300.000 -20.93%
1995 6.100.000 29.51%
1996 9.800.000 37.76%
1997 2.200.000 -345.45%
1998 -700.000 414.29%
1999 200.000 450%
2000 20.311.000 99.02%
2001 17.761.000 -14.36%
2002 10.654.000 -66.71%
2003 12.094.000 11.91%
2004 9.626.000 -25.64%
2005 18.450.000 47.83%
2006 28.906.000 36.17%
2007 20.453.000 -41.33%
2008 -18.672.000 209.54%
2009 6.481.000 388.1%
2010 -5.223.000 224.09%
2011 1.019.000 612.56%
2012 9.817.000 89.62%
2013 18.699.000 47.5%
2014 26.381.000 29.12%
2015 34.326.000 23.15%
2016 38.273.000 10.31%
2017 24.709.000 -54.89%
2018 31.357.000 21.2%
2019 47.054.000 33.36%
2020 15.217.000 -209.22%
2021 18.133.000 16.08%
2022 7.491.000 -142.06%
2023 276.000 -2614.13%
2024 -6.620.000 104.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CAMP4 Therapeutics Corporation Gross Profit
Year Gross Profit Growth
1986 -1.300.000
1987 3.700.000 135.14%
1988 3.000.000 -23.33%
1989 2.600.000 -15.38%
1990 3.500.000 25.71%
1991 3.500.000 0%
1992 8.400.000 58.33%
1993 13.500.000 37.78%
1994 13.300.000 -1.5%
1995 16.800.000 20.83%
1996 23.700.000 29.11%
1997 16.500.000 -43.64%
1998 14.000.000 -17.86%
1999 13.500.000 -3.7%
2000 26.421.000 48.9%
2001 30.755.000 14.09%
2002 22.881.000 -34.41%
2003 20.533.000 -11.44%
2004 17.666.000 -16.23%
2005 41.378.000 57.31%
2006 52.746.000 21.55%
2007 49.401.000 -6.77%
2008 18.495.000 -167.1%
2009 38.126.000 51.49%
2010 22.390.000 -70.28%
2011 29.558.000 24.25%
2012 42.019.000 29.66%
2013 56.893.000 26.14%
2014 79.931.000 28.82%
2015 87.404.000 8.55%
2016 102.959.000 15.11%
2017 143.352.000 28.18%
2018 150.890.000 5%
2019 147.764.000 -2.12%
2020 143.303.000 -3.11%
2021 122.405.000 -17.07%
2022 121.886.000 -0.43%
2023 109.011.000 -11.81%
2024 70.296.000 -55.07%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CAMP4 Therapeutics Corporation Net Profit
Year Net Profit Growth
1986 -5.700.000
1987 200.000 2950%
1988 100.000 -100%
1989 -900.000 111.11%
1990 200.000 550%
1991 -500.000 140%
1992 1.600.000 131.25%
1993 3.100.000 48.39%
1994 1.600.000 -93.75%
1995 2.500.000 36%
1996 5.000.000 50%
1997 600.000 -733.33%
1998 -2.700.000 122.22%
1999 -1.400.000 -92.86%
2000 -1.393.000 -0.5%
2001 5.209.000 126.74%
2002 4.464.000 -16.69%
2003 5.160.000 13.49%
2004 5.714.000 9.7%
2005 8.076.000 29.25%
2006 14.562.000 44.54%
2007 -31.188.000 146.69%
2008 -84.149.000 62.94%
2009 -49.665.000 -69.43%
2010 -10.851.000 -357.7%
2011 -3.283.000 -230.52%
2012 5.218.000 162.92%
2013 44.626.000 88.31%
2014 11.803.000 -278.09%
2015 16.508.000 28.5%
2016 16.940.000 2.55%
2017 -7.151.000 336.89%
2018 16.617.000 143.03%
2019 18.398.000 9.68%
2020 -78.774.000 123.36%
2021 -21.157.000 -272.33%
2022 -31.148.000 32.08%
2023 -32.490.000 4.13%
2024 -340.016.000 90.44%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CAMP4 Therapeutics Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1986 -1
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 1 0%
2007 -1 100%
2008 -4 66.67%
2009 -2 -50%
2010 0 0%
2011 0 0%
2012 0 0%
2013 2 100%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 1 0%
2020 -2 100%
2021 -1 0%
2022 -1 0%
2023 -1 0%
2024 -9 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CAMP4 Therapeutics Corporation Free Cashflow
Year Free Cashflow Growth
1990 -200.000
1991 -100.000 -100%
1992 500.000 120%
1993 -700.000 171.43%
1994 -3.100.000 77.42%
1995 400.000 875%
1996 6.900.000 94.2%
1997 -8.700.000 179.31%
1998 200.000 4450%
1999 4.700.000 95.74%
2000 -5.059.000 192.9%
2001 3.172.000 259.49%
2002 10.779.000 70.57%
2003 3.809.000 -182.99%
2004 2.401.000 -58.64%
2005 10.177.000 76.41%
2006 20.084.000 49.33%
2007 13.895.000 -44.54%
2008 -2.835.000 590.12%
2009 12.929.000 121.93%
2010 1.406.000 -819.56%
2011 -388.000 462.37%
2012 11.356.000 103.42%
2013 14.745.000 22.98%
2014 20.683.000 28.71%
2015 21.208.000 2.48%
2016 43.083.000 50.77%
2017 17.834.000 -141.58%
2018 58.555.000 69.54%
2019 35.733.000 -63.87%
2020 -10.648.000 435.58%
2021 17.229.000 161.8%
2022 -17.516.000 198.36%
2023 -34.032.000 48.53%
2024 -522.000 -6419.54%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CAMP4 Therapeutics Corporation Operating Cashflow
Year Operating Cashflow Growth
1990 200.000
1991 300.000 33.33%
1992 1.500.000 80%
1993 2.300.000 34.78%
1994 -300.000 866.67%
1995 3.400.000 108.82%
1996 10.300.000 66.99%
1997 -5.300.000 294.34%
1998 3.000.000 276.67%
1999 6.000.000 50%
2000 293.000 -1947.78%
2001 7.509.000 96.1%
2002 12.313.000 39.02%
2003 5.479.000 -124.73%
2004 5.094.000 -7.56%
2005 12.536.000 59.37%
2006 22.380.000 43.99%
2007 16.723.000 -33.83%
2008 -1.476.000 1232.99%
2009 13.760.000 110.73%
2010 2.472.000 -456.63%
2011 857.000 -188.45%
2012 12.432.000 93.11%
2013 16.597.000 25.09%
2014 22.816.000 27.26%
2015 28.645.000 20.35%
2016 47.400.000 39.57%
2017 25.796.000 -83.75%
2018 66.894.000 61.44%
2019 47.740.000 -40.12%
2020 11.544.000 -313.55%
2021 28.585.000 59.62%
2022 -4.218.000 777.69%
2023 -22.932.000 81.61%
2024 1.830.000 1353.11%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CAMP4 Therapeutics Corporation Capital Expenditure
Year Capital Expenditure Growth
1990 400.000
1991 400.000 0%
1992 1.000.000 60%
1993 3.000.000 66.67%
1994 2.800.000 -7.14%
1995 3.000.000 6.67%
1996 3.400.000 11.76%
1997 3.400.000 0%
1998 2.800.000 -21.43%
1999 1.300.000 -115.38%
2000 5.352.000 75.71%
2001 4.337.000 -23.4%
2002 1.534.000 -182.72%
2003 1.670.000 8.14%
2004 2.693.000 37.99%
2005 2.359.000 -14.16%
2006 2.296.000 -2.74%
2007 2.828.000 18.81%
2008 1.359.000 -108.09%
2009 831.000 -63.54%
2010 1.066.000 22.05%
2011 1.245.000 14.38%
2012 1.076.000 -15.71%
2013 1.852.000 41.9%
2014 2.133.000 13.17%
2015 7.437.000 71.32%
2016 4.317.000 -72.27%
2017 7.962.000 45.78%
2018 8.339.000 4.52%
2019 12.007.000 30.55%
2020 22.192.000 45.89%
2021 11.356.000 -95.42%
2022 13.298.000 14.6%
2023 11.100.000 -19.8%
2024 2.352.000 -371.94%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CAMP4 Therapeutics Corporation Equity
Year Equity Growth
1986 1.300.000
1987 1.700.000 23.53%
1988 2.200.000 22.73%
1989 1.800.000 -22.22%
1990 2.000.000 10%
1991 2.000.000 0%
1992 3.700.000 45.95%
1993 7.300.000 49.32%
1994 12.200.000 40.16%
1995 14.900.000 18.12%
1996 22.900.000 34.93%
1997 24.100.000 4.98%
1998 21.400.000 -12.62%
1999 20.100.000 -6.47%
2000 27.752.000 27.57%
2001 29.624.000 6.32%
2002 37.580.000 21.17%
2003 58.623.000 35.9%
2004 65.363.000 10.31%
2005 158.288.000 58.71%
2006 176.109.000 10.12%
2007 151.251.000 -16.43%
2008 73.420.000 -106.01%
2009 23.199.000 -216.48%
2010 19.199.000 -20.83%
2011 17.602.000 -9.07%
2012 24.977.000 29.53%
2013 117.549.000 78.75%
2014 133.147.000 11.71%
2015 151.385.000 12.05%
2016 189.447.000 20.09%
2017 163.995.000 -15.52%
2018 198.916.000 17.56%
2019 205.653.000 3.28%
2020 137.919.000 -49.11%
2021 95.085.000 -45.05%
2022 75.402.000 -26.1%
2023 14.307.000 -427.03%
2024 -74.139.000 119.3%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CAMP4 Therapeutics Corporation Assets
Year Assets Growth
1986 10.100.000
1987 7.100.000 -42.25%
1988 7.600.000 6.58%
1989 4.600.000 -65.22%
1990 5.900.000 22.03%
1991 4.800.000 -22.92%
1992 9.100.000 47.25%
1993 16.000.000 43.13%
1994 19.600.000 18.37%
1995 22.100.000 11.31%
1996 32.600.000 32.21%
1997 29.500.000 -10.51%
1998 27.800.000 -6.12%
1999 25.500.000 -9.02%
2000 55.552.000 54.1%
2001 49.812.000 -11.52%
2002 56.688.000 12.13%
2003 89.597.000 36.73%
2004 97.642.000 8.24%
2005 196.755.000 50.37%
2006 204.346.000 3.71%
2007 229.703.000 11.04%
2008 143.041.000 -60.59%
2009 69.647.000 -105.38%
2010 56.953.000 -22.29%
2011 55.485.000 -2.65%
2012 51.481.000 -7.78%
2013 150.771.000 65.85%
2014 179.265.000 15.89%
2015 202.617.000 11.53%
2016 384.363.000 47.28%
2017 407.674.000 5.72%
2018 472.993.000 13.81%
2019 603.626.000 21.64%
2020 495.805.000 -21.75%
2021 433.805.000 -14.29%
2022 391.581.000 -10.78%
2023 380.120.000 -3.02%
2024 281.241.000 -35.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CAMP4 Therapeutics Corporation Liabilities
Year Liabilities Growth
1986 8.800.000
1987 5.400.000 -62.96%
1988 5.400.000 0%
1989 2.800.000 -92.86%
1990 3.900.000 28.21%
1991 2.800.000 -39.29%
1992 5.400.000 48.15%
1993 8.700.000 37.93%
1994 7.400.000 -17.57%
1995 7.200.000 -2.78%
1996 9.700.000 25.77%
1997 5.400.000 -79.63%
1998 6.100.000 11.48%
1999 5.300.000 -15.09%
2000 27.458.000 80.7%
2001 19.532.000 -40.58%
2002 19.108.000 -2.22%
2003 30.974.000 38.31%
2004 32.279.000 4.04%
2005 38.467.000 16.09%
2006 28.237.000 -36.23%
2007 78.452.000 64.01%
2008 69.621.000 -12.68%
2009 46.448.000 -49.89%
2010 37.754.000 -23.03%
2011 37.883.000 0.34%
2012 26.504.000 -42.93%
2013 33.222.000 20.22%
2014 46.118.000 27.96%
2015 51.232.000 9.98%
2016 194.916.000 73.72%
2017 243.679.000 20.01%
2018 274.077.000 11.09%
2019 397.973.000 31.13%
2020 357.886.000 -11.2%
2021 338.720.000 -5.66%
2022 316.179.000 -7.13%
2023 365.813.000 13.57%
2024 355.380.000 -2.94%

CAMP4 Therapeutics Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.07
Net Income per Share
-2.71
Price to Earning Ratio
-0.15x
Price To Sales Ratio
0x
POCF Ratio
3.05
PFCF Ratio
-0.21
Price to Book Ratio
-0.2
EV to Sales
0.77
EV Over EBITDA
49.84
EV to Operating CashFlow
41.7
EV to FreeCashFlow
-66.37
Earnings Yield
-6.77
FreeCashFlow Yield
-4.66
Market Cap
0,00 Bil.
Enterprise Value
0,20 Bil.
Graham Number
10.99
Graham NetNet
-6.6

Income Statement Metrics

Net Income per Share
-2.71
Income Quality
-0.05
ROE
11.01
Return On Assets
-0.32
Return On Capital Employed
-0.48
Net Income per EBT
1.01
EBT Per Ebit
1.02
Ebit per Revenue
-0.75
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.16
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.35
Operating Profit Margin
-0.75
Pretax Profit Margin
-0.77
Net Profit Margin
-0.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.13
Free CashFlow per Share
-0.08
Capex to Operating CashFlow
-1.63
Capex to Revenue
-0.03
Capex to Depreciation
-0.37
Return on Invested Capital
-0.55
Return on Tangible Assets
-0.43
Days Sales Outstanding
97.76
Days Payables Outstanding
100.25
Days of Inventory on Hand
73.12
Receivables Turnover
3.73
Payables Turnover
3.64
Inventory Turnover
4.99
Capex per Share
-0.21

Balance Sheet

Cash per Share
1,02
Book Value per Share
-1,98
Tangible Book Value per Share
-3.16
Shareholders Equity per Share
-1.98
Interest Debt per Share
6.63
Debt to Equity
-3.26
Debt to Assets
0.86
Net Debt to EBITDA
49.68
Current Ratio
1.69
Tangible Asset Value
-0,12 Bil.
Net Current Asset Value
-0,19 Bil.
Invested Capital
-3.26
Working Capital
0,07 Bil.
Intangibles to Total Assets
0.16
Average Receivables
0,07 Bil.
Average Payables
0,05 Bil.
Average Inventory
31940500
Debt to Market Cap
366.35

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CAMP4 Therapeutics Corporation Dividends
Year Dividends Growth

CAMP4 Therapeutics Corporation Profile

About CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CEO
Mr. Joshua Mandel-Brehm
Employee
58
Address
One Kendall Square Bldg 1400 West, 3rd Floor
Cambridge, 02139

CAMP4 Therapeutics Corporation Executives & BODs

CAMP4 Therapeutics Corporation Executives & BODs
# Name Age
1 Dr. Leonard I. Zon M.D.
Founder
70
2 Dr. Daniel Tardiff Ph.D.
Vice President & Head of Discovery
70
3 Dr. Yuri Maricich M.B.A., M.D.
Chief Medical Officer
70
4 Dr. David Bumcrot Ph.D.
Chief Scientific Officer & Senior Vice President of Research
70
5 Mr. Caleb Moore
Chief Business Operations Officer & SVice President of Portfolio Strategy & Business Operations
70
6 Dr. Satya Kuchimanchi Ph.D.
Senior Vice President of Technical Operations
70
7 Mr. Joshua Mandel-Brehm
Chief Executive Officer, President & Director
70
8 Ms. Kelly Gold
Chief Financial Officer
70
9 Ms. Michelle Gates
Senior Vice President & Chief People Officer
70
10 Dr. Richard A. Young Ph.D.
Founder & Independent Director
70

CAMP4 Therapeutics Corporation Competitors